Trial Profile
A phase I / II study to evaluate the effect of pegylated-Interferon-2alpha on overall survival in patients with relapsed haematological malignancy after allogeneic haematopoietic progenitor cell transplantation
Status:
Recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 16 Jul 2019
Price :
$35
*
At a glance
- Drugs Peginterferon alfa-2a (Primary)
- Indications Haematological malignancies
- Focus Therapeutic Use
- 19 Jul 2012 New trial record